Wall Street analysts predict that Endocyte, Inc. (NASDAQ:ECYT) will post ($0.18) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.20). Endocyte reported earnings per share of ($0.27) during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The company is scheduled to report its next earnings report on Wednesday, May 9th.
On average, analysts expect that Endocyte will report full year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($0.98) to ($0.70). For the next fiscal year, analysts expect that the business will report earnings of ($0.84) per share, with EPS estimates ranging from ($0.91) to ($0.72). Zacks’ earnings per share averages are a mean average based on a survey of research firms that cover Endocyte.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The company had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 40.33% and a negative net margin of 78,662.86%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) EPS.
In other Endocyte news, VP Christopher P. Leamon sold 5,036 shares of Endocyte stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $9.07, for a total value of $45,676.52. Following the completion of the sale, the vice president now directly owns 143,470 shares in the company, valued at $1,301,272.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.86% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ECYT. AXA acquired a new stake in Endocyte in the fourth quarter valued at approximately $101,000. Dimensional Fund Advisors LP raised its position in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares during the period. Bank of New York Mellon Corp raised its position in shares of Endocyte by 46.5% in the fourth quarter. Bank of New York Mellon Corp now owns 51,313 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 16,283 shares during the period. EAM Investors LLC bought a new position in shares of Endocyte in the fourth quarter valued at approximately $420,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Endocyte by 1,443.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 173,759 shares of the biopharmaceutical company’s stock valued at $744,000 after purchasing an additional 162,498 shares during the period. Hedge funds and other institutional investors own 30.42% of the company’s stock.
Shares of ECYT stock traded down $0.15 during trading on Friday, hitting $8.30. 707,106 shares of the company were exchanged, compared to its average volume of 3,417,708. The stock has a market cap of $572.44, a P/E ratio of -8.30 and a beta of 0.48. Endocyte has a twelve month low of $1.17 and a twelve month high of $11.54.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.